Evaluation of the Effect of Botulinum Toxin Type-A Injection Prior to Surgical Correction of Complete Unilateral Cleft Lip Repair by Modified Millard Cheiloplasty
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03047499 |
Recruitment Status : Unknown
Verified February 2017 by Mostafa Khairy, Cairo University.
Recruitment status was: Recruiting
First Posted : February 9, 2017
Last Update Posted : February 9, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Esthetic Outcome of Injection of Botulinum Toxin Type-A in Cleft Lip Repair | Drug: Botulinum toxin type A |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 2 participants |
Observational Model: | Case-Control |
Time Perspective: | Cross-Sectional |
Target Follow-Up Duration: | 6 Months |
Official Title: | Evaluation of the Effect of Botulinum Toxin Type-A Injection Prior to Surgical Correction of Complete Unilateral Cleftlip Repair by Modified Millard Cheiloplasty |
Estimated Study Start Date : | February 15, 2017 |
Estimated Primary Completion Date : | October 15, 2017 |
Estimated Study Completion Date : | November 15, 2017 |

Group/Cohort | Intervention/treatment |
---|---|
Scar Length |
Drug: Botulinum toxin type A
Botulinum toxin type-A injection |
Vancouver scar scale |
Drug: Botulinum toxin type A
Botulinum toxin type-A injection |
Scar width |
Drug: Botulinum toxin type A
Botulinum toxin type-A injection |
- Scar Length [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 3 Months to 6 Months (Child) |
Sexes Eligible for Study: | All |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Primary cleft lip
Exclusion Criteria:
- Cleft palate

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03047499
Contact: Mostafa Ayman Khairy | 00201001155527 | mostafakhairy100@hotmail.com |
Egypt | |
Cairo University | Recruiting |
Cairo, Egypt, 72427 | |
Contact: Rehab Tariq Elsharkawy, Dr |
Responsible Party: | Mostafa Khairy, Cairo University |
ClinicalTrials.gov Identifier: | NCT03047499 |
Other Study ID Numbers: |
CEBC-CU-2017-02-04 |
First Posted: | February 9, 2017 Key Record Dates |
Last Update Posted: | February 9, 2017 |
Last Verified: | February 2017 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Cleft Lip Lip Diseases Mouth Diseases Stomatognathic Diseases Mouth Abnormalities Stomatognathic System Abnormalities Congenital Abnormalities Botulinum Toxins Botulinum Toxins, Type A |
abobotulinumtoxinA Acetylcholine Release Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Cholinergic Agents Neurotransmitter Agents Physiological Effects of Drugs Neuromuscular Agents Peripheral Nervous System Agents |